奥米卡替麦卡比在因心力衰竭恶化住院患者中的潜在适用性。 - Suppr

Potential Applicability of Omecamtiv Mecarbil to Patients Hospitalized for Worsening Heart Failure.

作者信息

Harrington Josephine, Sun Jie-Lena, Fonarow Gregg C, Heitner Stephen B, Divanji Punag H, Allen Larry A, Alhanti Brooke, Yancy Clyde W, Albert Nancy M, DeVore Adam D, Felker G Michael, Greene Stephen J

机构信息

Division of Cardiology, Duke University School of Medicine, Durham, North Carolina; Duke Clinical Research Institute, Durham, North Carolina.

Duke Clinical Research Institute, Durham, North Carolina.

出版信息

Am J Cardiol. 2023 Oct 15;205:524-526. doi: 10.1016/j.amjcard.2023.08.013. Epub 2023 Sep 4.

DOI:10.1016/j.amjcard.2023.08.013

PMID:37666729

Abstract

摘要

相似文献

Potential Applicability of Omecamtiv Mecarbil to Patients Hospitalized for Worsening Heart Failure.

Am J Cardiol. 2023 Oct 15;205:524-526. doi: 10.1016/j.amjcard.2023.08.013. Epub 2023 Sep 4.

Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF.

J Am Coll Cardiol. 2021 Jul 13;78(2):97-108. doi: 10.1016/j.jacc.2021.04.065. Epub 2021 May 17.

Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.

JAMA. 2022 Jul 19;328(3):259-269. doi: 10.1001/jama.2022.11016.

Omecamtiv Mecarbil: A Myosin Motor Activator Agent with Promising Clinical Performance and New in vitro Results.

Curr Med Chem. 2018;25(15):1720-1728. doi: 10.2174/0929867325666171222164320.

Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF.

JACC Heart Fail. 2020 Apr;8(4):329-340. doi: 10.1016/j.jchf.2019.12.001. Epub 2020 Feb 6.

Population Pharmacokinetic Properties of Omecamtiv Mecarbil in Healthy Subjects and Patients With Heart Failure With Reduced Ejection Fraction.

J Cardiovasc Pharmacol. 2022 Apr 1;79(4):539-548. doi: 10.1097/FJC.0000000000001207.

[CLINICAL EFFICACY OF A REPRESENTATIVE OF A NEW CLASS OF INOTROPIC AGENTS - THE DIRECT ACTIVATOR OF MYOSIN OF CARDIOMYOCYTES OMECAMTIV MECARBIL IN HEART FAILURE WITH A REDUCED EJECTION FRACTION].

Georgian Med News. 2021 Sep(318):165-171.

Perspectives of a myosin motor activator agent with increased selectivity.

Can J Physiol Pharmacol. 2018 Jul;96(7):676-680. doi: 10.1139/cjpp-2017-0741. Epub 2018 May 24.

Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial.

Eur Heart J. 2022 Jun 14;43(23):2212-2220. doi: 10.1093/eurheartj/ehac144.

Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.

Expert Opin Investig Drugs. 2016;25(1):117-27. doi: 10.1517/13543784.2016.1123248. Epub 2015 Dec 19.

引用本文的文献

Eligibility of Outpatients with Chronic Heart Failure for Vericiguat and Omecamtiv Mecarbil: From Clinical Trials to the Real-World Practice.

J Clin Med. 2025 Mar 13;14(6):1951. doi: 10.3390/jcm14061951.

Beyond quadruple therapy: the potential roles for ivabradine, vericiguat, and omecamtiv mecarbil in the therapeutic armamentarium.

Heart Fail Rev. 2024 Sep;29(5):949-955. doi: 10.1007/s10741-024-10412-y. Epub 2024 Jun 29.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Potential Applicability of Omecamtiv Mecarbil to Patients Hospitalized for Worsening Heart Failure.

作者信息

机构信息

Division of Cardiology, Duke University School of Medicine, Durham, North Carolina; Duke Clinical Research Institute, Durham, North Carolina.

Duke Clinical Research Institute, Durham, North Carolina.

出版信息

Am J Cardiol. 2023 Oct 15;205:524-526. doi: 10.1016/j.amjcard.2023.08.013. Epub 2023 Sep 4.

DOI:10.1016/j.amjcard.2023.08.013

PMID:37666729

Abstract

摘要

相似文献

Potential Applicability of Omecamtiv Mecarbil to Patients Hospitalized for Worsening Heart Failure.

Am J Cardiol. 2023 Oct 15;205:524-526. doi: 10.1016/j.amjcard.2023.08.013. Epub 2023 Sep 4.

Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF.

J Am Coll Cardiol. 2021 Jul 13;78(2):97-108. doi: 10.1016/j.jacc.2021.04.065. Epub 2021 May 17.

Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.

JAMA. 2022 Jul 19;328(3):259-269. doi: 10.1001/jama.2022.11016.

Omecamtiv Mecarbil: A Myosin Motor Activator Agent with Promising Clinical Performance and New in vitro Results.

Curr Med Chem. 2018;25(15):1720-1728. doi: 10.2174/0929867325666171222164320.

Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF.

JACC Heart Fail. 2020 Apr;8(4):329-340. doi: 10.1016/j.jchf.2019.12.001. Epub 2020 Feb 6.

Population Pharmacokinetic Properties of Omecamtiv Mecarbil in Healthy Subjects and Patients With Heart Failure With Reduced Ejection Fraction.

J Cardiovasc Pharmacol. 2022 Apr 1;79(4):539-548. doi: 10.1097/FJC.0000000000001207.

[CLINICAL EFFICACY OF A REPRESENTATIVE OF A NEW CLASS OF INOTROPIC AGENTS - THE DIRECT ACTIVATOR OF MYOSIN OF CARDIOMYOCYTES OMECAMTIV MECARBIL IN HEART FAILURE WITH A REDUCED EJECTION FRACTION].

Georgian Med News. 2021 Sep(318):165-171.

Perspectives of a myosin motor activator agent with increased selectivity.

Can J Physiol Pharmacol. 2018 Jul;96(7):676-680. doi: 10.1139/cjpp-2017-0741. Epub 2018 May 24.

Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial.

Eur Heart J. 2022 Jun 14;43(23):2212-2220. doi: 10.1093/eurheartj/ehac144.

Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.

Expert Opin Investig Drugs. 2016;25(1):117-27. doi: 10.1517/13543784.2016.1123248. Epub 2015 Dec 19.

引用本文的文献

Eligibility of Outpatients with Chronic Heart Failure for Vericiguat and Omecamtiv Mecarbil: From Clinical Trials to the Real-World Practice.

J Clin Med. 2025 Mar 13;14(6):1951. doi: 10.3390/jcm14061951.

Beyond quadruple therapy: the potential roles for ivabradine, vericiguat, and omecamtiv mecarbil in the therapeutic armamentarium.

Heart Fail Rev. 2024 Sep;29(5):949-955. doi: 10.1007/s10741-024-10412-y. Epub 2024 Jun 29.

Potential Applicability of Omecamtiv Mecarbil to Patients Hospitalized for Worsening Heart Failure.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Potential Applicability of Omecamtiv Mecarbil to Patients Hospitalized for Worsening Heart Failure.

作者信息

机构信息

出版信息

相似文献

引用本文的文献